Nevertheless it has been reported that combination of trastuzumab and pertuzumab provides a more efficient blockade of HER2 signaling than either antibody alone, leading to a more effective inhibition of tumor growth in HER2-positive breast cancer, gastric cancer and lung cancer [26–28]. The gene discussed is ERBB2; the disease is neoplasm.